Código QR (código de barras bidimensional)

Cost-Effectiveness of Adjuvant Osimertinib With and Without Chemotherapy for Surgically Resected NSCLC

Introduction: Osimertinib is now approved as adjuvant therapy for stage IB to III NSCLC with EGFR mutations. Nevertheless, this treatment is lengthy and expensive. Its cost-effectiveness profile as monotherapy versus combination with chemotherapy is unknown. In this context, we investigate the cost-...

ver descrição completa

Na minha lista:
Principais autores: Angelos Vasilopoulos, BS, Alexander Pohlman, MD, Ayham Odeh, MD, K. Robert Shen, MD, Julia M. Coughlin, MD, Zaid M. Abdelsattar, MD, MS, FACS
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2025-06-01
coleção:JTO Clinical and Research Reports
Assuntos:
Lung cancer
Targeted therapy
EGFR
Osimertinib
Cost-effectiveness
Acesso em linha:http://www.sciencedirect.com/science/article/pii/S2666364325000499
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados